Clinical Trial Update: A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of LY3499446 in advanced solid tumors with KRAS G12C has been terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• LY3499446

Snippet

Sponsor: Eli Lilly and Company | Conditions: Advanced Solid Tumor, Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-11-24